Johnson & Johnson 11.04 Billion Shares Traded Rank 54th as Stock Surges 0.90% on Positive Clinical Trial Results

On June 12, 2025, Johnson & Johnson (JNJ) closed with a trading volume of 11.04 billion, ranking 54th in the day's stock market. The stock price increased by 0.90%.

Johnson & Johnson announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib in combination with venetoclax and azacitidine for acute myeloid leukemia. The study demonstrated encouraging antileukemic activity and a favorable safety profile, particularly for patients with specific genetic mutations.

Johnson & Johnson also reported that more than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24. Improvement in both joint and skin symptoms reinforce TREMFYA®.

Additionally, Johnson & Johnson announced promising Phase 1 trial results for JNJ-79635322 (JNJ-5322), a novel trispecific antibody for treating relapsed or refractory multiple myeloma. Early results from the trial show a promising response in heavily pretreated multiple myeloma patients.